EP3973990A4 - Promotor for permeation into cell layer, composition for facilitating drug agent absorption, and pharmaceutical composition - Google Patents

Promotor for permeation into cell layer, composition for facilitating drug agent absorption, and pharmaceutical composition Download PDF

Info

Publication number
EP3973990A4
EP3973990A4 EP20779344.9A EP20779344A EP3973990A4 EP 3973990 A4 EP3973990 A4 EP 3973990A4 EP 20779344 A EP20779344 A EP 20779344A EP 3973990 A4 EP3973990 A4 EP 3973990A4
Authority
EP
European Patent Office
Prior art keywords
composition
promotor
permeation
cell layer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20779344.9A
Other languages
German (de)
French (fr)
Other versions
EP3973990A1 (en
Inventor
Takeo Usui
Yoko NAGUMO
Minagi MUKAIYAMA
Yoshio Hayashi
Atsuhiko Taniguchi
Chihiro Uchiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tsukuba NUC
Original Assignee
University of Tsukuba NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tsukuba NUC filed Critical University of Tsukuba NUC
Publication of EP3973990A1 publication Critical patent/EP3973990A1/en
Publication of EP3973990A4 publication Critical patent/EP3973990A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP20779344.9A 2019-03-25 2020-03-19 Promotor for permeation into cell layer, composition for facilitating drug agent absorption, and pharmaceutical composition Pending EP3973990A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019057323 2019-03-25
PCT/JP2020/012446 WO2020196315A1 (en) 2019-03-25 2020-03-19 Promotor for permeation into cell layer, composition for facilitating drug agent absorption, and pharmaceutical composition

Publications (2)

Publication Number Publication Date
EP3973990A1 EP3973990A1 (en) 2022-03-30
EP3973990A4 true EP3973990A4 (en) 2023-07-19

Family

ID=72611947

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20779344.9A Pending EP3973990A4 (en) 2019-03-25 2020-03-19 Promotor for permeation into cell layer, composition for facilitating drug agent absorption, and pharmaceutical composition

Country Status (5)

Country Link
US (1) US20220226479A1 (en)
EP (1) EP3973990A4 (en)
JP (1) JP6975437B2 (en)
CN (1) CN113874045B (en)
WO (1) WO2020196315A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3726324A1 (en) * 1987-08-07 1989-02-16 Hoechst Ag CYCLOPEPTIDE AS RESORPTION FOLDER IN APPLICATION TO THE MEAT
TW274552B (en) * 1992-05-26 1996-04-21 Hoechst Ag
MX2014015876A (en) * 2012-07-09 2015-03-19 Hoffmann La Roche Cell penetrating peptides to target eif4e.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEUDENS NIELS ET AL: "Membrane Interactions of Natural Cyclic Lipodepsipeptides of the Viscosin Group", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 1859, no. 3, 20 December 2016 (2016-12-20), pages 331 - 339, XP029898767, ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2016.12.013 *
MNIF INÈS ET AL: "Lipopeptide surfactants: Production, recovery and pore forming capacity", PEPTIDES, vol. 71, 1 September 2015 (2015-09-01), AMSTERDAM, NL, pages 100 - 112, XP055580289, ISSN: 0196-9781, DOI: 10.1016/j.peptides.2015.07.006 *
See also references of WO2020196315A1 *

Also Published As

Publication number Publication date
CN113874045B (en) 2023-11-24
EP3973990A1 (en) 2022-03-30
CN113874045A (en) 2021-12-31
JP6975437B2 (en) 2021-12-01
WO2020196315A1 (en) 2020-10-01
US20220226479A1 (en) 2022-07-21
JPWO2020196315A1 (en) 2021-09-27

Similar Documents

Publication Publication Date Title
EP4035657A4 (en) Drug composition containing abiraterone acetate, and preparation method therefor and application thereof
BR112012003283A8 (en) pharmaceutically acceptable salt of an amphiphilic photosensitizing agent, pharmaceutical composition, product, kit, use of a pharmaceutically acceptable salt of an amphiphilic photosensitizing agent, and method of introducing a drug molecule into the cytosol of a cell in a patient.
BRPI0921519A8 (en) Packaged solid sufentanil drug dosage form and method for preventing oxidative degradation of said dosage form
EP3965772A4 (en) Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
EP4079756A4 (en) Proliferative liver organoid, metaboliccaly activated liver organoid, and use thereof
EP3786167A4 (en) Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
EP3714887A4 (en) Pharmaceutical composition for topical administration and preparation method therefor
EP3481381A4 (en) Oral dosage form with drug composition, barrier layer and drug layer
EP4079734A4 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP3939610A4 (en) Combined pharmaceutical composition for treating small cell lung cancer
EP3858846A4 (en) Nucleic acid nanocarrier medicament, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP3744316A4 (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
EP4223759A4 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
EP3686212A4 (en) Pentacyclic triterpene compound and preparation method therefor, and pharmaceutical composition and use thereof
EP3865488A4 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
EP4066860A4 (en) Polyethylene glycol conjugated drug, and preparation method therefor and use thereof
EP3821911A4 (en) Nucleic acid nanoparticles, pharmaceutical composition comprising same, drug comprising doxorubicin and preparation method therefor
EP3741364A4 (en) Pharmaceutical composition, patch and manufacturing method thereof, analgesic method, and application
EP3750537A4 (en) Pharmaceutical composition, excipient for the composition and use of the composition
EP4071170A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
EP3992194A4 (en) Benzodiazepine compound, preparation method therefor, and use thereof in medicine
EP3973990A4 (en) Promotor for permeation into cell layer, composition for facilitating drug agent absorption, and pharmaceutical composition
EP4053151A4 (en) Keratin bd-1, preparation method, and pharmaceutical composition and use thereof
EP3950677A4 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
EP3884943A4 (en) Application of chidamide in combination with r-chop, and drug combination

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230621

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 11/00 20060101ALI20230615BHEP

Ipc: A61K 47/42 20170101ALI20230615BHEP

Ipc: A61K 45/00 20060101AFI20230615BHEP